Haemonetics (NYSE:HAE) Posts Quarterly Earnings Results, Beats Estimates By $0.06 EPS

Key Points

• Haemonetics beat quarterly estimates: EPS was $1.14 versus the $1.08 consensus, while revenue rose 5.5% year over year to $339.38 million, exceeding expectations of $327.86 million.
• Management raised fiscal 2027 guidance to reported revenue growth of 5%–8% and organic growth of 4%–7%, supported by strong plasma demand, Persona PLUS adoption and renewed growth in interventional technologies.
• Operating cash flow more than tripled to $52 million, but tariffs, inflation, transportation costs and weakness in certain MedSurg and OEM businesses remain potential headwinds.

Haemonetics (NYSE:HAE - Get Free Report) posted its earnings results on Thursday. The medical instruments supplier reported $1.14 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $1.08 by $0.06, FiscalAI reports. Haemonetics had a net margin of 7.12% and a return on equity of 27.55%. The company had revenue of $339.38 million during the quarter, compared to the consensus estimate of $327.86 million. During the same period in the previous year, the firm posted $1.10 earnings per share. The firm's quarterly revenue was up 5.5% on a year-over-year basis.

Here are the key takeaways from Haemonetics' conference call:

• Haemonetics raised fiscal 2027 guidance, now expecting reported revenue growth of 5%–8% and organic growth of 4%–7%, following first-quarter revenue growth of 6% and adjusted EPS growth of 4% to $1.14.
• Plasma revenue increased 8% organically, supported by double-digit disposable growth, share gains, strong collection volumes, and the early rollout of Persona PLUS, which is delivering more than 5% yield improvements for early adopters.
• Interventional technologies returned to growth, led by low-double-digit vascular closure growth. The VASCADE MVP XL indication expansion, new clinical evidence, and stronger sales execution are supporting account wins and increased utilization in PFA and other large-bore procedures.
• Cash generation was strong, with operating cash flow tripling year over year to $52 million and trailing-12-month free-cash-flow conversion reaching 106% of adjusted net income. The company used cash to repay $100 million of revolver debt and retains flexibility for growth investments and opportunistic share repurchases.
• External cost pressures remain a headwind, including tariffs, transportation and oil-related costs, material inflation, and higher personnel expenses. Slower cell-salvage capital upgrades and weakness in OEM and esophageal-cooling businesses also weighed on parts of MedSurg and interventional technologies.

Haemonetics Price Performance

NYSE HAE traded up $2.48 on Friday, hitting $87.50. The company had a trading volume of 657,064 shares, compared to its average volume of 737,142. The company has a debt-to-equity ratio of 1.40, a current ratio of 3.08 and a quick ratio of 1.87. The company's fifty day moving average price is $76.98 and its 200-day moving average price is $66.52. The company has a market capitalization of $3.98 billion, a PE ratio of 42.89, a PEG ratio of 1.71 and a beta of 0.52. Haemonetics has a 12-month low of $47.31 and a 12-month high of $88.58.

Trending Headlines about Haemonetics

Here are the key news stories impacting Haemonetics this week:

• Positive Sentiment: Haemonetics reported fiscal Q1 2027 earnings of $1.14 per share, exceeding the $1.07–$1.08 consensus range. Revenue rose 5.5% year over year to $339.4 million, also comfortably ahead of expectations near $327.9 million. The earnings and sales beats indicate continued operating momentum. Haemonetics Tops Q1 Earnings and Revenue Estimates
• Positive Sentiment: Management raised its fiscal 2027 outlook and now expects reported revenue growth of approximately 5% to 8%. The improved forecast, following a strong first quarter, supports the view that demand and execution are better than previously anticipated. Haemonetics Raises Fiscal 2027 Revenue Guidance
• Positive Sentiment: BTIG Research raised its Haemonetics price target from $84 to $96 and maintained a “buy” rating, implying additional upside based on the company’s earnings performance and outlook. BTIG Raises Haemonetics Price Target
• Neutral Sentiment: Citigroup lifted its price target from $79 to $92, while retaining a “neutral” rating. The higher target reflects improved estimates but suggests limited conviction at the current valuation. Citigroup Analyst Update
• Neutral Sentiment: JPMorgan raised its target from $62 to $86 but maintained a “neutral” rating. The revised target remains slightly below the recent trading level, signaling that valuation may constrain further gains despite the improved outlook. JPMorgan Analyst Update

Analysts Set New Price Targets

A number of research firms have weighed in on HAE. Mizuho lifted their price objective on Haemonetics from $85.00 to $90.00 and gave the company an "outperform" rating in a research note on Wednesday, July 15th. BTIG Research upped their target price on Haemonetics from $84.00 to $96.00 and gave the stock a "buy" rating in a research note on Thursday. Citigroup raised their target price on Haemonetics from $79.00 to $92.00 and gave the stock a "neutral" rating in a report on Friday. Bank of America upgraded Haemonetics from a "neutral" rating to a "buy" rating and lifted their price target for the company from $72.00 to $80.00 in a research report on Friday, May 22nd. Finally, Raymond James Financial restated an "outperform" rating and issued a $105.00 price objective on shares of Haemonetics in a research report on Friday. One investment analyst has rated the stock with a Strong Buy rating, six have issued a Buy rating and four have assigned a Hold rating to the stock. According to MarketBeat, the company currently has an average rating of "Moderate Buy" and an average target price of $90.89.

Institutional Trading of Haemonetics

Several institutional investors have recently modified their holdings of the stock. Kemnay Advisory Services Inc. acquired a new position in shares of Haemonetics during the 4th quarter worth about $26,000. EverSource Wealth Advisors LLC lifted its stake in Haemonetics by 2,640.0% in the 2nd quarter. EverSource Wealth Advisors LLC now owns 411 shares of the medical instruments supplier's stock valued at $31,000 after buying an additional 396 shares in the last quarter. Kestra Advisory Services LLC acquired a new stake in Haemonetics in the 4th quarter worth about $34,000. Caitong International Asset Management Co. Ltd boosted its holdings in Haemonetics by 20,925.0% in the 3rd quarter. Caitong International Asset Management Co. Ltd now owns 841 shares of the medical instruments supplier's stock worth $41,000 after buying an additional 837 shares during the last quarter. Finally, UMB Bank n.a. increased its stake in Haemonetics by 110.9% during the 4th quarter. UMB Bank n.a. now owns 582 shares of the medical instruments supplier's stock worth $47,000 after buying an additional 306 shares in the last quarter. Institutional investors and hedge funds own 99.67% of the company's stock.

Haemonetics Company Profile

Haemonetics Corporation is a global provider of blood management solutions that support the collection, processing and transfusion of blood and blood products. The company's offerings are designed to enhance patient safety and operational efficiency for blood centers, hospitals and plasma collection facilities. Haemonetics serves healthcare providers worldwide by delivering integrated systems, software and consumables that address critical needs throughout the continuum of blood management.

The company's product portfolio includes automated apheresis and plasma collection systems, surgical blood salvage and coagulation monitoring devices, and pathogen reduction technologies.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source